Gujarat's active Covid tally crosses 1,200 mark; 1 death reported officially, hospitals confirm 4 more
The number of active Covid cases in Gujarat reached 1,227 on Tuesday, just a day after it crossed the 1,000 mark. Meanwhile, while the state health department has officially reported just one Covid death, at least four other patients with comorbidities have lost their lives during the latest surge in cases.
A total of 105 patients were discharged on Tuesday. Of the active cases, 23 patients have been admitted to various hospitals, while 1,204 are in home isolation.
While four women have recently died due to Covid in Ahmedabad, a man admitted to Rajkot Civil Hospital died on Tuesday, confirmed the hospital administration. The state government, however, has confirmed only one death in Ahmedabad after the fresh spate of cases.
The five deaths and co-morbidities
The 55-year-old man who died on Tuesday, had been suffering from hypertension since the last one year. There was a recent detection of diabetes. He had been admitted to Rajkot Civil Hospital after he complained of breathlessness along with fever. He was also a patient of acute leukemia (blood cancer). The patient, who was under treatment at a private hospital initially, was later transferred to AIIMS Rajkot after doctors conducted an HRCT scan. AIIMS Rajkot then referred him to Rajkot Civil Hospital, where he died on Tuesday. Notably, the man had taken all three doses of Covid vaccination.
Ahmedabad's LG Hospital has reported deaths of two Covid patients with comorbidities. One 47-year-old woman from Danilimda with hypertension was admitted on May 23. Her condition deteriorated rapidly, suffering septiscemia, leading to further complications and death on May 28. Another was an 18-year-old who had delivered a child just a week before being admitted to the hospital on May 30. She was said to have developed cardiomyopathy and died at the hospital on June 2.
Two other patients, who were admitted at GMERS Sola Civil Hospital in Ahmedabad, also lost their lives. A 20-year-old Covid patient, who was admitted on May 13, delivered a pre-term baby in the seventh month of her pregnancy on May 27, and was kept on BiPAP oxygen support. On May 30, while she tested negative for Covid, her three-day-old child tested positive. On June 3, the woman suddenly left the hospital with her child, taking Discharge Against Medical Advice (DAMA). She died at her residence later that day. This is the only Covid death to have been confirmed and reported by the state government during the recent spike in cases.
The second patient to have died at GMERS Sola Civil Hospital was a 16-year-old girl from Sabarkantha, who was admitted on June 4. Medical tests confirmed that she had tested positive for Covid-19 and Hepatitis B virus. She died during treatment on June 8.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
38 minutes ago
- Time of India
Lens on new pharmacy colleges in Maharashtra over complaints about forged maps, NOCs, occupancy certificates for approvals
Mumbai: Pharmacy colleges established in the state over the last three years have come under scrutiny following complaints about forged documents, including certified maps and occupation certificates for buildings, being submitted for approvals. More than 115 colleges offering B Pharm and nearly 200 offering D Pharm have emerged during this period. Acting on these complaints, state govt has ordered a re-inspection of all such institutions to verify the authenticity of their documents and whether they meet all the requirements. The aim is to contain the mushrooming of colleges in the state and prevent vacancies of seats during admissions. Data from the Directorate of Technical Education (DTE) shows that over 30% of seats remained vacant last year in both B Pharm and D Pharm courses in the state. In a recent order, govt stated that several complaints were received by the higher and technical education minister regarding pharmacy, diploma, degree, and postgraduate institutions that were granted approval by submitting bogus documents such as certified maps, no-objection certificates (NOCs), occupancy certificates, and utility certificates to state and central govts. The order directed: "The validity of these documents should be verified with the relevant authorities, and an institution-wise inspection report should be submitted to confirm whether adequate educational facilities are available. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Novi ortopedski sandali za moške poletje 2025. Fiippy KUPITE ZDAJ Undo " The Pharmacy Council of India (PCI) gives approval to new institutions once affiliating universities and respective state govts provide them with NOCs. Milind Umekar, president of the Indian Pharmaceutical Congress Association, a federation of five pharmaceutical associations, highlighted two key reasons behind the rapid increase in pharmacy institutions in Maharashtra. "The demand for pharmacy courses surged after the Covid-19 pandemic, as people began recognising growing opportunities in the pharmaceutical industry, including research, clinical studies, pharmacovigilance, formulation and development, and drug or vaccine manufacturing. India ranks third globally in drug production by volume and is among the top exporters. Secondly, before 2022, the PCI imposed a moratorium on setting up new institutes. Once this was lifted following a court order, several colleges rushed to introduce pharmacy programmes," he said, adding that a comprehensive re-inspection exercise is crucial to ensure all institutions meet PCI norms, including the required number of qualified faculty, infrastructure, and laboratories. A representative from a college management said that in the last three years, many colleges were given NOCs by the respective universities, mainly Dr Babasaheb Ambedkar Technological University (BATU) Lonere, without any physical inspection and based on documents submitted by the institutions. "BATU has the highest number of affiliated pharmacy colleges in the state, and most may have come up in the last three years. The university, set up exclusively for technical colleges in the state, faces a severe shortage of manpower, impacting the quality of education in the affiliated institutions," he alleged. A govt official said that officials from the Maharashtra State Board of Technical Education and DTE have started carrying out the inspection exercise, adding that no timeline has been provided.
Time of India
an hour ago
- Time of India
Maharashtra reports 19 new COVID-19 cases
Mumbai: The state recorded 19 new Covid-19 cases on Sunday, taking the state's tally of the viral infections in this calendar year to 2,337, a health department official said. Of the new cases, eight are from Mumbai, six from Pune and its outskirts, two from the limits of the Pimpri Chhinchwad Municipal Corporation near Pune and three from Sangli and nearby areas. No fresh fatality due to coronavirus has been reported in the last four days, an official statement said. The health department said it has conducted 25,519 Covid-19 tests across the state since Jan 1, adding that 2,007 patients have recovered to date. Meanwhile, Mumbai has reported 942 cases, including 509 in June, so far this year. Since Thursday, no deaths due to the viral infection have been reported in the state. A total of 32 patients have succumbed to the virus in the state since January 1, of whom 31 had comorbidities (pre-existing health conditions that can increase the risk of severe illness), the statement said.
Time of India
7 hours ago
- Time of India
A new HIV drug promises 99.9% protection. But it's making Indian health activists wary; Why?
The US Food and Drug Administration (FDA) has approved lenacapavir, a new injectable drug that claims to offer 99.9% protection against HIV. But concerns are being raised in India over its affordability and accessibility, particularly through the public healthcare system. The injection costs around ₹24 lakh ($28,218) for two doses administered six months apart. Lenacapavir belongs to the class of HIV prevention drugs known as pre-exposure prophylaxis (PrEP). However, India's National AIDS Control Organisation (NACO) has not included PrEP in its public programmes so far. "Our govt distributes condoms to break HIV transmission, it provides antiretroviral therapy drugs to prevent parent-to-child transmission of HIV, but it hasn't ever given PrEP to youngsters who are likely to indulge in high-risk behaviour," said health activist Ganesh Acharya. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hanoi: Unsold Furniture Liquidation 2024 (Prices May Surprise You) Unsold Furniture | Search Ads Learn More Undo He added that NACO had made it mandatory for its counselling centres to provide information on PrEP a couple of years ago. He also expressed concern that 75% of the 88% people diagnosed with HIV in Mumbai in 2023–24 were from the 15–49 age group. PrEP, however, remains available only in the private sector. Experts call for government action, tiered pricing PrEP has existed for over a decade and is widely used in developed countries. In India, public health discussions around PrEP only began recently. Live Events A doctor from a government hospital said, "They set up a committee, then a white paper was brought out that served as a backgrounder for guidelines that were drawn up last year. However, there has been no development since." Dr Ishwar Gilada of the People's Health Organisation (India) said, "The govt should distribute PrEP to check the spread of the disease, which has only been increasing in recent years. The total number of HIV-positive people in India increased from 2.2 million to 2.5 million in a few years." According to him, sexually transmitted infections have been rising in Mumbai. "A recent survey in Mumbai among men who have sex with men found that 60% of them were positive for the human papilloma virus. While gonorrhoea and chlamydia vanished 25 years ago, their numbers are shooting up," he said. He suggested a three-tier pricing structure: full price for those who can afford it, subsidised pricing for some, and free access for those unable to pay. NACO officials were not available for comment. India has also not approved HIV self-testing kits. "We have self-testing kits for pregnancy, diabetes, and Covid, but policymakers fear about the mental health of people after a positive result in self-testing HIV kits," said Dr Gilada. A senior doctor suggested that similar fears may be behind the delay in rolling out PrEP publicly, as officials worry it might encourage risky behaviour. Hope for lower-cost versions as UNAIDS urges price drop Bala from Bombay Gay called lenacapavir a "monumental milestone forward in HIV treatment and prevention," but added that the current price point makes it inaccessible in India. "So, we have to wait and see if prices will come down over time," he said. Dr Gilada expressed hope that Indian manufacturers licensed by Gilead Sciences might eventually offer the injection at less than $100 per year. "India can do it," he said. UNAIDS, in a recent statement, urged Gilead Lifesciences to reduce the price of the new drug to improve global access.
